FindTrial
Sign In

To find out how the latest drugs will Help Breast and Ovarian Cancer Patients in Eastern India with Gene Problems.

Outcomes of Breast and Ovarian cancer patients with HRD/BRCA gene alterations treated with PARP inhibitors at a tertiary care hospital in Eastern India. - BROCA-PI

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/11/059748
Enrollment
340
Registered
2023-11-10
Start date
Unknown
Completion date
Unknown
Last updated
2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C509- Malignant neoplasm of breast of unspecified site Health Condition 2: C569- Malignant neoplasm of unspecifiedovary

Interventions

Control Intervention1: NIL: NIL

Sponsors

INSTITUTE OF MEDICAL SCIENCES AND SUM HOSPITAL
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Newly diagnosed Breast and ovarian cancer patients greater than 18 years with HRD/BRCA gene alterations registered in the department of Medical Oncology, IMS and SUM hospital

Exclusion criteria

Exclusion criteria: 1. Patients less than 18 years of age 2. Patients not meeting the above-mentioned criteria 3. Patients or patient relatives who do not consent to the testing 4. Patients with BRCA1 and/or BRCA2 mutations that are considered to be non-detrimental (eg, “Variants of uncertain clinical significance ? or “Variant of unknown significance ? or “Variant, favor polymorphism ? or “benign polymorphism, ? etc).

Design outcomes

Primary

MeasureTime frame
Progression-free survival (PFS)Timepoint: 2 years—

Secondary

MeasureTime frame
1. To determine Overall survival among HRD/ BRCA positive Breast and ovary patients taking PARP inhibitors (Olaparib/Rucaparib). 2. To determine Safety, Efficacy among HRD/ BRCA positive Breast and ovary patients taking PARP inhibitors (Olaparib/Rucaparib). 3. To determine the prevalence of BRCA/ HRD positive mutations among breast and ovarian cancer patients 4. Identifying the clinical and pathological profile of the patients testing positive for HRD/ g BRCA/t BRCA mutations. 5. To find out the hindrances in doing HRD/ g BRCA/ t BRCA mutation testing and in obtaining PARP inhibitors (Olaparib/Rucaparib). Timepoint: 3years,5years—

Countries

India

Contacts

Public ContactSoumya Surath Panda

Institute of Medical Sciences and SUM Hospital

drgbiswas@gmail.com9937500878

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026